Faron Pharmaceuticals Ltd (LON:FARN) says early results from a proof of concept trial for immunotherapy cancer treatment Clevegen are encouraging.
There were noticeable increases in the body’s natural killer cells in the first two patients treated and no toxicity increase.
WATCH: Faron Pharma makes encouraging start in Clevegen solid tumour trial
Markku Jalkanen, chief executive, said: "We are very encouraged by these findings, and by the potential early clinical benefits indicated through the biochemical and tumour load indicators, following several lines of previous ineffective treatments.
"These biomarker data will prove valuable to help determine the optimal dose as the trial continues and we look forward to generating further data to assess the urability of effect and efficacy in a larger number of patients."
The MATINS trial is a Phase I/II clinical study to investigate the safety and efficacy of Clevegen on selected metastatic/inoperable solid tumours in melanoma, hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancers.